#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Insulinoma Acute graft versus host disease Chondrodystrophy Non-small cell lung cancer metastatic Pleural mesothelioma Systemic candida Cystic fibrosis lung Vulval cancer Red blood cell abnormality Fatty acid oxidation disorder Breast cancer Oropharyngeal squamous cell carcinoma ROHHAD syndrome Pyoderma gangrenosum Neuroendocrine tumour of the lung More trials…

    Learn about Rare Diseases

    Lymphatic malformation – Diagnostics Immunodeficiency congenital – Treatment Acquired haemophilia – Treatment Carcinoid syndrome – Basic Information Retinitis pigmentosa – Trials in Disease Angiosarcoma metastatic – Trials in Disease Hereditary neuropathic amyloidosis – Basic Information Angiosarcoma non-metastatic – Diagnostics Pulmonary sarcoidosis – Life with Disease Alexander disease – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tralokinumab Nofazinlimab Indometacin Anselamimab Afatinib Azd0901 Morphine Sulfate Quercetin Glasdegib Telisotuzumab Vedotin Jnj-77242113 Other Immunosuppressants Theophylline Fazirsiran Olmesartan Medoxomil Rimegepant HYDROMORPHONE HYDROCHLORIDE Minocycline Nipocalimab Tinzaparin More therapies…

    Learn about Your Condition

    Hereditary angioedema Congenital myopathy Carotid artery occlusion Pneumonia bacterial Primary hyperaldosteronism Growth hormone deficiency Bone sarcoma Endometrial cancer stage II Malignant mast cell neoplasm Bronchiectasis Bladder cancer HER2 negative breast cancer Pleural mesothelioma malignant Hypochondroplasia Immunodeficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • A Study Testing TUB-040 Combined with Standard Cancer Drugs for Patients with High-Grade Epithelial Serous or Endometrioid Ovarian Cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    • Tub-040
    Belgium

  • A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Everolimus
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium France Germany Italy The Netherlands +2

  • A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Mirvetuximab Soravtansine
    Belgium Czechia Denmark France Spain

  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Fluorouracil
    • Folinic Acid
    Belgium Czechia France Germany Hungary Italy +2

  • A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein

    Recruiting

    2 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • INCB123667
    Belgium Spain

  • A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia Denmark France Germany +7

  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Study of icotrokinra for adults with moderately to severely active Crohn’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amivantamab
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Hungary +6

  • A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Dolutegravir Sodium
    • Emtricitabine
    • Lamivudine
    Belgium France Germany Italy Poland Portugal +1
Previous Page
1 … 4 5 6 7 8 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!